Nipocalimab Demonstrates Efficacy for Myasthenia Gravis and Sjogren’s Disease Treatment

In a recent press release, Johnson and Johnson reported positive results from their trials looking at an antibody known as nipocalimab for the treatment of myasthenia gravis (MG) and Sjogren’s Disease (SjD).

In its phase 3 trial for MG they reported a statistically significant reduction in scores of disease compared to those in the placebo group. In its phase 2 trial for SjD they also reported a significant statistical improvement of scores of disease compared to placebo. 

Earlier results from Johnson and Johnson also reported benefit of nipocalimab for those with rheumatoid arthritis and hemolytic disease of the fetus and newborn.

Overall, these results suggest that nipocalimab has potential for many autoimmune diseases. The next steps are to seek FDA approval for MG and to continue onto Phase 3 trials for those with SjD.